Doxorubicin is one of the most employed anticancer drugs, but its efficacy is limited by the onset of adverse effects such as drug resistance, due to the drug efflux via P-glycoprotein (Pgp). Several factors are associated to a high Pgp activity, including the amount of cholesterol in plasma membrane, which is essential to maintain the pump function. In this work we started from the following observations: 1) the drug-resistant colon cancer HT29-dx cells had a higher content of cholesterol in plasma membrane than drug-sensitive HT29 cells and a higher activity of Pgp, which was decreased by the cholesterol-lowering agent β-methyl-cyclodextrin; 2) HT29-dx cells showed a higher synthesis of endogenous cholesterol and a higher expression of the low-density lipoprotein receptor (LDLR); 3) the anti-cholesterolemic drug simvastatin reduced the cholesterol synthesis, increased the synthesis of LDLR and lowered the Pgp activity in resistant cells. In order to circumvent drug resistance we designed a new liposomal doxorubicin, conjugated with a recombinant LDLR-binding peptide from human apoB100: this LDL-masked doxorubicin ("apo-Lipodox") was efficiently internalized by a LDLR-driven endocytosis and induced cytotoxic effects in HT29-dx cells, reversing their drug resistance. Its efficacy was further increased by simvastatin, which up-regulates the LDLR levels and contemporarily reduces the Pgp activity, thus increasing the liposomes uptake and limiting the drug efflux. We propose that the association of liposomal doxorubicin and statins may be a future promising strategy to reverse drug-resistance in human cancer cells.

A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells

KOPECKA, JOANNA;CAMPIA, IVANA;OLIVERO, Paolo;PESCARMONA, Gianpiero;GHIGO, Dario Antonio;BOSIA, Amalia;RIGANTI, Chiara
2011-01-01

Abstract

Doxorubicin is one of the most employed anticancer drugs, but its efficacy is limited by the onset of adverse effects such as drug resistance, due to the drug efflux via P-glycoprotein (Pgp). Several factors are associated to a high Pgp activity, including the amount of cholesterol in plasma membrane, which is essential to maintain the pump function. In this work we started from the following observations: 1) the drug-resistant colon cancer HT29-dx cells had a higher content of cholesterol in plasma membrane than drug-sensitive HT29 cells and a higher activity of Pgp, which was decreased by the cholesterol-lowering agent β-methyl-cyclodextrin; 2) HT29-dx cells showed a higher synthesis of endogenous cholesterol and a higher expression of the low-density lipoprotein receptor (LDLR); 3) the anti-cholesterolemic drug simvastatin reduced the cholesterol synthesis, increased the synthesis of LDLR and lowered the Pgp activity in resistant cells. In order to circumvent drug resistance we designed a new liposomal doxorubicin, conjugated with a recombinant LDLR-binding peptide from human apoB100: this LDL-masked doxorubicin ("apo-Lipodox") was efficiently internalized by a LDLR-driven endocytosis and induced cytotoxic effects in HT29-dx cells, reversing their drug resistance. Its efficacy was further increased by simvastatin, which up-regulates the LDLR levels and contemporarily reduces the Pgp activity, thus increasing the liposomes uptake and limiting the drug efflux. We propose that the association of liposomal doxorubicin and statins may be a future promising strategy to reverse drug-resistance in human cancer cells.
2011
149
196
205
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T3D-51726MN-1-1&_cdi=4944&_user=525216&_pii=S0168365910007911&_origin=search&_coverDate=10%2F12%2F2010&_sk=999999999&view=c&wchp=dGLbVzb-zSkWb&md5=06ae3e9451b00936e6dfdb1cf61bffd2&ie=/sdarticle.pdf
P-glycoprotein; Doxorubicin; Liposomes; LDL receptor; Simvastatin
Kopecka J; Campia I; Olivero P; Pescarmona GP; Ghigo D; Bosia A; Riganti C
File in questo prodotto:
File Dimensione Formato  
Kopecka, J Contr rel, Suppl 2011.jpg

Accesso riservato

Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 23 kB
Formato JPEG
23 kB JPEG   Visualizza/Apri   Richiedi una copia
Kopecka, Cover story, J Contr rel, 2011.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 97.6 kB
Formato Adobe PDF
97.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Kopecka, J Control Rel, 2011.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 998.94 kB
Formato Adobe PDF
998.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/80151
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 55
social impact